FRX Fennec Pharmaceuticals Inc
- 7.090
- -0.110-1.53%
Fennec Pharmaceuticals Inc News
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Cuts Target Price to $13
Buy Rating Affirmed for Fennec Pharmaceuticals Amidst PEDMARK's Long-Term Growth Potential
Express News | Fennec Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $13 From $15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are Reducing Their Forecasts For This Year
Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
Maxim Group Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $22
Buy Rating for Fennec Pharmaceuticals Bolstered by Pedmark's Market Expansion and New Leadership
Fennec Pharmaceuticals Analyst Ratings
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Announces Target Price $15
Wedbush Adjusts Fennec Pharmaceuticals' PT to $48 From $40, Keeps Neutral Rating
Express News | Fennec Pharmaceuticals, Inc. : Craig-Hallum Cuts Target Price to $15 From $17
Q2 2024 Fennec Pharmaceuticals Inc Earnings Call
Express News | Fennec Pharmaceuticals Inc : Wedbush Cuts Target Price to $14 From $16
Capital One Financial Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Cuts Target Price to $15
Optimistic Buy Rating for Fennec Pharmaceuticals Amidst Pedmark's Market Expansion and Strong Financial Outlook
Fennec Pharmaceuticals Welcomes New CEO, Posts Strong Q2
Earnings Call: Fennec Pharmaceuticals Achieved Net Revenues of $7.3 Million
Fennec Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Earnings Call Summary | Fennec Pharmaceuticals(FENC.US) Q2 2024 Earnings Conference
No Data